

Key word index to volume 10

- [¹⁸F- α -methyl]tryrosine, 329
 [^{99m}Tc]ethylenedicysteine, 685
- 10-Hydroxycamptothecin, 569
 256 carcinosarcoma Walker, 785
 2-Deoxyglucose/Na azide, 171
 4-Substituted 5-nitrophthalimides, 777
 5-Aza-2'-8-deoxycytidine, 471
 5-Ethyl-2'-8-deoxyuridine, 561
 5-Fluorouracil, 275, 337, 519, 617, 699
 5-Fluorouracil modulation, 561
 5-Methylcytosine, 471
 6-hydroxymethyl-acyfulvene, 837
 9-Aminocamptothecin, 647, 705
 9-Nitrocamptothecin, 317
- Abasic site, 55
 Acute leukemia, 267
 Adjuvant immunotherapy, 139
 Adozelesin, 295
 Adult, 837
 Advanced breast cancer, 155
 Advanced colorectal cancer, 283, 337
 Advanced gastric cancer, 729
 Advanced ovarian cancer, 533
 Advanced soft tissue sarcoma, 873
 Adverse effects, 289
 Albumins, 405, 785
 Alkylating agents, 55, 663
 Allergic reaction, 289
 Ambulatory medicine, 385
 Anemia, 375
 Angiogenesis, 249
 Anthracenes, 163
 Antiandrogens, 791
 Antiangiogenesis, 685
 Anticancer activity, 419
 Anticancer drugs, 119, 139, 791, 853
- Anticancer therapy, 249
 Antifolate resistance, 677
 Antimetastatic agents, 229
 Antineoplastic therapy, 33
 Antisense, 249
 Antitumor, 591, 829
 Aplidine, 879
 Apoptosis, 119, 489, 569, 845, 895
 Apoptotic cell death (apoptosis), 323
 Arginase, 113
 Artificial endonucleases, 55
 Astrocytoma, 861
 ATP, 431
 Azotemia, 275
- Benzamides, 79
 Bicalutamide, 791
 Biodistribution, 89
 Bioreductive, 577
 Bioreductive activation, 777
 Bisdioxopiperazine, 47
 Bizelesin, 295
 BMS-181174, 821
 Blood-brain barrier, 861
 Breast cancer, 89, 471, 625
- Camptothecin, 47, 655
 Canaline, 113
 Canavanine, 113
 Cancer, 361, 895
 Carboplatin, 533
 Cardiotoxicity, 671
 Carzelesin, 295
 Catalytic cycle, 551
 CCNU, 179
 CDC2, 67
 Cell adhesiveness, 429
 Cell cycle, 67, 103, 569, 895
 Cell signaling, 249
 Cellular drug accumulation, 921
 Cellular uptake, 213
 Cervical neoplasms, 641
 CFU-GM, 213
 CGP 41, 251, 67
 Chemosensitivity, 179, 431, 437, 797
 Chemotherapy, 147, 195, 235, 283, 431, 605, 735, 741, 873
 Chemotherapy-induced alopecia, 393
 CHO, 47
 Chronotherapy, 385
- Circadian rhythms, 385
 Cisplatin, 9, 203, 219, 235, 361, 369, 419, 445, 457, 465, 545, 735, 829, 911
 Cleavable complex formation, 39
 Clinical pharmacokinetics, 705
 Colchicine, 685
 Colon cancer, 519
 Colorectal cancer, 385, 617, 741
 Colorectal carcinoma, 329
 Combination chemotherapy, 267
 Combination treatment, 895
 Combined modality therapy, 369
 Compatibility, 879
 Concomitant medications, 1
 Continuous infusion, 729
 Copenhagen rats, 405
 Cost, 605
 Cost-effectiveness, 605
 Cystitis, 375
 Cyclin B₁, 67
 Cyclosporin, 511
 Cytokine, 97
 Cytokines, 219
 Cytoskeleton, 537
 Cytotoxic interactions, 213
 Cytotoxicity, 47, 537, 577, 903, 921
- DACH platinum, 195
 Daunorubicin, 921
 Declopramide (3-chloroprocain-amide), 79
 Dehydration, 275
 Delayed decoupling, 171
 Dendrimer, 767
 Development, 431
 Dexamethasone, 465
 Dexrazoxane, 47
 Dextran-conjugated doxorubicin, 171
 Diarylsulfonylurea, 303
 Diazenes, 853
 Diethylhexyl phthalate, 879
 Dihydropyrimidine dehydrogenase, 561
 Distamycin, 397, 663
 Distribution, 163
 DNA, 47
- DNA binding, 647
 DNA cleavage, 39, 489, 551, 749
 DNA damage, 195
 DNA damage response, 219
 DNA fragmentation, 323
 DNA methylation, 471
 DNA synthesis, 489
 DNA topoisomerase I, 195
 Doxorubicin, 671, 719, 873, 921
 Drug carriers, 405, 785
 Drug resistance, 139, 663, 719, 853, 861, 873
 Drug-resistant, 267
 DT-diaphorase, 777
 DTPA-adriamycin, 89
 Dunning prostate cancer, 405
 DX-8951f, 655
- Eastern Cooperative Oncology Group, 245
 Economic evaluation, 283
 Electrochemotherapy, 139
 Electrogenic therapy, 139
 Electroporation, 139
 Encephalopathy, 275
 EORTC, 873
 Epirubicin, 257
 EPR effect, 767
 Erythrocytes, 705
Escherichia coli nitroreductase, 777
 Etoposide, 807, 815
 Excision repair, 55
- First-line therapy, 155
 Flow cytometry, 569
 Flutamide, 791
 Folinic acid, 519, 699
 Polyglutamate synthetase, 505, 677
 Fotemustine, 413
- Gallic acid, 845
 Gallium, 477
 Gamma linoleic acids, 413
 Gastric cancer, 293, 355
 Gemcitabine, 33, 155, 445, 525, 533, 625, 693, 699
 Gene-specific repair, 545
 Germ cell tumor, 711
 GF120918, 719

Key word index to volume 10

- Glioblastoma, 413
 Glioma, 179
 Glutathione, 663
 Granisetron, 465
 Growth inhibition, 457

 Head and neck carcinoma, 369
 Hemolysis, 879
 Hemolytic uremic syndrome, 533
 Hep G2 cells, 569
 Hepatic artery infusion, 385
 Hepatocellular carcinoma, 815
 Hepatocellular carcinoma cells, 323
 High-dose 5-fluorouracil, 355
 High-dose ifosfamide, 25
 HPMA copolymers, 767
 Human tumor cloning, 303, 655
 Human tumor cloning assay, 97, 309, 837
 Human tumor colony-forming units, 295
 Hydroxyurea, 429
 Hyperammonemia, 275
 Hyperthermia, 317
 Hysterectomy, 641

 ICRF-187, 47
 Idarubicin, 671
 Ifosfamide, 873
 Imaging, 329
In vitro, 705
In vitro cytotoxicity, 413
In vitro sensitivity, 103
 Independant review, 693
 Indole, 577
 Infection, 275
 Infusion, 625
 Infusion devices, 879
 Infusion pump, 355
 Inhibitors, 551
 Intercalators, 163
 Interferon- α , 369
 Interleukin-2, 219
 Interleukin-11, 97
 Intoplicine, 17, 889
 Intravenous, 807
 Investigational agents, 1
 Irinotecan (CPT11), 9, 617

 kDNA decantation assay, 397
 Kinetic analysis, 647
 KF22678, 829
 KRN8602, 267
 KW-2149, 633

 L1210 cell viability, 477, 489
 L1210 leukemia cells, 457, 749
 Leucovorin, 355
 Leukemia cells, 317, 677, 797
 Lewis lung carcinoma, 489
 Limited sampling models, 9
 Liposome, 911, 921
 Liver metastases, 385
 Low-dose cytosine arabinoside, 289
 Luciferase, 437
 Lung cancer, 845
 Lung cancer cell lines, 119
 LY295501, 303
 Lymphoma, 797

 Macromolecule synthesis, 749
 Makaluvamine, 39
 Malignant pleural mesothelioma, 33
 Medical care consumption, 617
 Melanoma, 245, 437, 735
 Melphalan, 245
 Metabolism, 329
 Metabolization, 147
 Metastasis, 129, 235, 429
 Metastatic breast cancer, 525
 Metastatic soft-tissue sarcoma, 453
 Methotrexate, 293
 Methotrexate-albumin, 405
 Methotrexate therapy, 405
 Methylacetylenic putrescine, 103
 Metoclopramide, 79
 MGBCP, 323
 MGI 114, 837
 MIA PaCa-2, 113
 Mice, 79
 Microtubule, 537
 Miotic index, 749
 Mitomycin C, 729
 Mitomycin C analog, 633, 821
 Mitotic index, 477, 489
 MKT 077, 309
 Mouse, 829
 Mouse fibrosarcoma, 235
 mRNA transcription, 677
 Multidrug resistance, 171, 663, 921
 Myelosuppression, 375

 Na⁺,K⁺-ATPase, 203
 Nausea, 375, 465
 NC 65, 229
 ND2001, 229

 Neo-adjuvant chemotherapy, 641
 Nephroprotection, 419
 Nephrotoxicity, 25, 203
 Neutropenia, 375
 New agents, 163
 New drugs, 431
 Non-apoptotic cell death, 103
 Non-small cell lung cancer, 605, 693
 N-ras, 545
 N-(2-chloroethyl)-N-nitro, 903
 NSC 645008, 889
 Nucleoside transport, 489, 749
 Nude mice, 229
 Nilutamide, 791

 O⁶-alkyl-guanine-DNA alkyltransferase, 179
 ODC activity, 103
 Oral, 807
 Oral squamous cell carcinoma, 203
 Oral trofosfamide, 453
 Ornithine decarboxylase, 797
 Osteosarcoma, 25
 Ovarian cancer, 257, 263
 Ovarian cells, 591
 Ovarian-342 tumor, 405

 Paclitaxel, 397, 605, 895
 Palliation, 283, 741
 Pancreatic cancer, 113, 699
 pBR322 relaxation assay, 397
 Pediatric, 837
 Peripheral blood lymphocytes, 219
 Peripheral blood stem cell transplantation, 711
 P-glycoprotein, 267, 719
 Pharmacokinetics, 9, 17, 79, 633, 719, 807, 889, 911
 Phase
 I, 1, 17, 393, 525, 633, 699, 821, 889
 II, 625, 873
 III, 617
 Platelet, 263
 Platinite, 767
 Platinum drugs, 213
 Polyamine metabolism, 103
 Polyamines, 323, 797
 Polyglutamation capacity, 677
 Polymer therapeutics, 767
 Polyvinyl chloride, 879
 Population, 807
 Potentiation, 55

 Precipitation, 879
 Pre-clinical models, 671
 Prodrug activation, 777
 Prolonged infusion, 525, 625
 Prostate cancer, 791
 Protein binding, 511
 Proteins, 705
 Pulmonary toxicity, 633
 Pyrimidines, 591

 Quercetin, 187
 Quinone, 577

 r α -2a-interferon, 519
 Raltitrexed, 505, 741, 873
 Randomized phase III trial, 257
 Rats, 79
 Rebound concentrations, 705
 Red blood cell, 147
 Regimen, 431
 Regimens, 337
 Religation, 551
 Renal cell carcinoma, 229
 Residualizing labels, 785
 Resistance, 457
 Response rates, 693
 Resveratrol, 187
 Retinoic acid receptor β , 471
 Retinoids, 361, 369
 Rhodacyanine dyes, 309
 RP 60475, 889
 Ruthenium, 129

 S 16020, 597
 Salvage chemotherapy, 729
 Sarcoma, 873
 Schedule dependency, 807
 Scintigraphy, 89, 785
 Small cell carcinoma, 641
 SN-38, 9
 SPI-077, 911
 Squamous cell carcinoma, 187, 369
 Stability, 879
 Staurosporine, 67
 Storage, 147
 Subacute encephalopathy, 293
 Sugar high-dose chemotherapy, 711
 Surface plasmon resonance, 647
 Synergism, 195, 445
 Synthesis, 777, 903
 System, 303

 Tamoxifen, 815, 895
 Taxanes, 213
 Taxol, 397

- Temozolomide, 179
Teniposide, 511, 605
Thermochemotherapy, 317
Thiazole, 577
Thiol group, 203
Three-dimensional cultures, 445
Thrombocytopenia, 375
Thymidylate synthase inhibitor, 283, 741
Time-schedule dependency, 597
Tiopronin, 419
Tirapazamine, 735
Tomudex, 283, 505, 741, 873
Topoisomerase I inhibitors, 655
Topoisomerase I mutants, 647
Topoisomerase II α , 551
Topoisomerase II, 39, 47, 397, 551, 597
Topotecan, 195, 263, 655
Toxicity, 263
Transforming growth factor- β 1, 457
Transport, 147
Treatment, 129, 337
Triptycenes, 749
Tubulin binding site and polymerization, 477, 489
Tumor, 129
Tumor cell growth and viability, 749
Tumor cells, 853
Tumor imaging, 685
Tumor progression, 235
Tumor targeting, 767
Tumor volume doubling time, 405
UCN-01, 67
UFT, 235
Vesnarinone, 119
Vinca alkaloids, 537
Vinflunine, 537
Vinorelbine, 537
Vitamin A, 361
Vitamin D $_3$, 393
Vomiting, 465
Walker-256 carcinoma, 405
Weight loss, 375
ZD1694, 741